{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/SNYNF/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:59:06.456Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6164,"canonical_name":"Sanofi","cik":"0001121404","uei":null,"lei":null,"duns":null,"ticker":"SNYNF"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":12,"clinical":70},"count":82,"timeline":[{"ts":"2026-07-22","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Sanofi — 2026-07-22","url_slug":"/sec/cik-0001121404/schedule-13g-a/0001172661-26-002731","accession_number":"0001172661-26-002731","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-07-17","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-306689","accession_number":"0001193125-26-306689","importance":30},{"ts":"2026-07-07","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-07-07","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-296990","accession_number":"0001193125-26-296990","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"11-K","title":"11-K — Sanofi — 2026-06-30","url_slug":"/sec/cik-0001121404/11-k/0001104659-26-079220","accession_number":"0001104659-26-079220","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"11-K","title":"11-K — Sanofi — 2026-06-30","url_slug":"/sec/cik-0001121404/11-k/0001104659-26-079229","accession_number":"0001104659-26-079229","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"NT 11-K","title":"NT 11-K — Sanofi — 2026-06-30","url_slug":"/sec/cik-0001121404/nt-11-k/0001104659-26-079194","accession_number":"0001104659-26-079194","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"NT 11-K","title":"NT 11-K — Sanofi — 2026-06-30","url_slug":"/sec/cik-0001121404/nt-11-k/0001104659-26-079195","accession_number":"0001104659-26-079195","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-06-24","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-280319","accession_number":"0001193125-26-280319","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-06-22","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-276766","accession_number":"0001193125-26-276766","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-06-12","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-268874","accession_number":"0001193125-26-268874","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-06-08","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-260613","accession_number":"0001193125-26-260613","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Sanofi","title":"Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07325292","excerpt":"[\"Multiple Sclerosis\"]","importance":60},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07272629","excerpt":"[\"Cardiac Repolarization\",\"Healthy Volunteers\"]","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Sanofi","title":"Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06052800","excerpt":"[\"Fabry Disease\"]","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Sanofi","title":"Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis","security_title":null,"status":"COMPLETED","accession_number":"NCT06099704","excerpt":"[\"Moderate to Severe Atopic Dermatitis\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Sanofi","title":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06141473","excerpt":"[\"Multiple Sclerosis\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Sanofi","title":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06141486","excerpt":"[\"Multiple Sclerosis\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Sanofi","title":"The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis","security_title":null,"status":"RECRUITING","accession_number":"NCT07467564","excerpt":"[\"Atopic Dermatitis\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Sanofi","title":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07135986","excerpt":"[\"Meningococcal Infection\",\"Healthy Volunteers\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)","security_title":"PHASE4","status":"NOT_YET_RECRUITING","accession_number":"NCT07135973","excerpt":"[\"Chronic Graft Versus Host Disease\"]","importance":25},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Sanofi","title":"An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps","security_title":"PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT07424144","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06241118","excerpt":"[\"Dermatitis Atopic\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Sanofi","title":"Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07516418","excerpt":"[\"Respiratory Syncytial Virus (RSV)\",\"Influenza A(H5N1)\"]","importance":30},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Sanofi","title":"First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04401020","excerpt":"[\"Neoplasm Malignant\"]","importance":30},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06290128","excerpt":"[\"Chronic Inflammatory Demyelinating Polyradiculoneuropathy\",\"Polyneuropathy, Inflammatory Demyelinating, Chronic\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Sanofi","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07103148","excerpt":"[\"Yellow Fever Immunization\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Sanofi","title":"Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials","security_title":"PHASE2,PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT05492578","excerpt":"[\"Dermatitis Atopic\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06500702","excerpt":"[\"Focal Segmental Glomerulosclerosis\",\"Glomerulonephritis Minimal Lesion\"]","importance":45},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Sanofi","title":"A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06691113","excerpt":"[\"Chronic Rhinosinusitis Without Nasal Polyps\"]","importance":45},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Sanofi","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT06695117","excerpt":"[\"COVID-19 Immunization\",\"Influenza Immunization\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Sanofi","title":"A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07190196","excerpt":"[\"Immunoglobulin G4 Related Disease\"]","importance":60},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07225569","excerpt":"[\"Hidradenitis Suppurativa\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Sanofi","title":"Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany","security_title":null,"status":"COMPLETED","accession_number":"NCT07002047","excerpt":"[\"Chlamydia Trachomatis\"]","importance":25},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Sanofi","title":"Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07007962","excerpt":"[\"Immune Thrombocytopenia\"]","importance":60},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Sanofi","title":"The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06975865","excerpt":"[\"Sickle Cell Disease\"]","importance":60},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Sanofi","title":"A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT02991469","excerpt":"[\"Juvenile Idiopathic Arthritis\"]","importance":45},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Sanofi","title":"A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07116031","excerpt":"[\"Chronic Graft Versus Host Disease\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07185009","excerpt":"[\"Ulcerative Colitis\"]","importance":60},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06834347","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":60},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06867094","excerpt":"[\"Colitis Ulcerative\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT06454240","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06914908","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06844214","excerpt":"[\"Myotonic Dystrophy\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07071558","excerpt":"[\"Respiratory Syncytial Virus Immunization\"]","importance":30},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Sanofi","title":"A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06714461","excerpt":"[\"Rheumatoid Arthritis\",\"Psoriatic Arthritis\"]","importance":25},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Sanofi","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07348692","excerpt":"[\"Pneumococcal Immunization\",\"Healthy Volunteers\"]","importance":60},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07412470","excerpt":"[\"Kidney Transplant Rejection\"]","importance":60},{"ts":"2026-04-27","kind":"sec.filing","form_type":"6-K","title":"6-K — Sanofi — 2026-04-27","url_slug":"/sec/cik-0001121404/6-k/0001193125-26-180848","accession_number":"0001193125-26-180848","importance":30},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Sanofi","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06834360","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":60},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Sanofi","title":"An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07184996","excerpt":"[\"Ulcerative Colitis\"]","importance":60},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Sanofi","title":"Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP","security_title":"PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT06859099","excerpt":"[\"Polyneuropathy, Inflammatory Demyelinating, Chronic\"]","importance":60},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06975722","excerpt":"[\"Ulcerative Colitis\"]","importance":45},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Sanofi","title":"Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05769777","excerpt":"[\"Dermatitis Atopic\"]","importance":45},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT06790121","excerpt":"[\"Dermatitis Atopic\"]","importance":45},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Sanofi","title":"A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07215234","excerpt":"[\"Geographic Atrophy\"]","importance":45},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06637631","excerpt":"[\"Crohn's Disease\"]","importance":45},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06407934","excerpt":"[\"Dermatitis Atopic\"]","importance":60},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Sanofi","title":"A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07146750","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Sanofi","title":"Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT01298323","excerpt":"[\"Locally Advanced or Metastatic Medullary Thyroid Cancer\",\"Medullary Thyroid Cancer\"]","importance":70},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Sanofi","title":"Long-Term Outcomes of Teplizumab in Routine Clinical Care","security_title":null,"status":"RECRUITING","accession_number":"NCT07360080","excerpt":"[\"Type 1 Diabetes\"]","importance":25},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Sanofi","title":"Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)","security_title":null,"status":"RECRUITING","accession_number":"NCT07457580","excerpt":"[\"Type 1 Diabetes\"]","importance":25},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Sanofi","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06676319","excerpt":"[\"Asthma\"]","importance":45},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Sanofi","title":"Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma","security_title":"PHASE4","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05097287","excerpt":"[\"Asthma\"]","importance":25},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Sanofi","title":"Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT04751487","excerpt":"[\"Chronic Obstructive Pulmonary Disease\"]","importance":70},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Sanofi","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07247188","excerpt":"[\"Sickle Cell Disease\"]","importance":60},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Sanofi","title":"Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes","security_title":null,"status":"RECRUITING","accession_number":"NCT07380711","excerpt":"[\"Chronic Obstructive Pulmonary Disease COPD\"]","importance":25},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria","security_title":null,"status":"RECRUITING","accession_number":"NCT07316114","excerpt":"[\"Chronic Spontaneous Urticaria\"]","importance":25},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06824194","excerpt":"[\"Pneumococcal Immunization\"]","importance":60},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05897424","excerpt":"[\"Alpha 1-Antitrypsin Deficiency\",\"Emphysema\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06791291","excerpt":"[\"Type 1 Diabetes Mellitus\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT06949358","excerpt":"[\"Acid Sphingomyelinase Deficiency\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT06015308","excerpt":"[\"Dermatitis Atopic\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)","security_title":null,"status":"RECRUITING","accession_number":"NCT06837454","excerpt":"[\"Atopic Dermatitis\"]","importance":25},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Sanofi","title":"Registry for Stage 2 Type 1 Diabetes","security_title":null,"status":"RECRUITING","accession_number":"NCT06481904","excerpt":"[\"Type 1 Diabetes\"]","importance":25},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Sanofi","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05263206","excerpt":"[\"Pruritus\"]","importance":60},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"Sanofi","title":"Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06891417","excerpt":"[\"Chlamydia Trachomatis Immunization\"]","importance":45},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","security_title":"PHASE4","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06716424","excerpt":"[\"Type 2 Diabetes\"]","importance":25},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire","security_title":null,"status":"COMPLETED","accession_number":"NCT06765187","excerpt":"[\"Influenza Immunization\",\"Health Volunteers\"]","importance":25},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Sanofi","title":"Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06258057","excerpt":"[\"Pertussis (Whooping Cough)\"]","importance":25},{"ts":"2026-04-03","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06984627","excerpt":"[\"Graves' Disease\"]","importance":45},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"Sanofi","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07282795","excerpt":"[\"Influenza Immunization\",\"Healthy Volunteers\"]","importance":25},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"Sanofi","title":"A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06958536","excerpt":"[\"Crohn's Disease\"]","importance":45}]}